OBT206

OBT206 is an antibody-drug conjugate (ADC) currently in the discovery stage of development by Oxford BioTherapeutics. Designed for the treatment of cancer, OBT206 consists of a monoclonal antibody conjugated to a cytotoxic payload via a chemical linker. The antibody component is intended to recognize and bind to a specific, though currently undisclosed, tumor-associated antigen, allowing for the targeted delivery of the cytotoxic agent directly into cancer cells while sparing healthy tissue. This program is part of Oxford BioTherapeutics' oncology pipeline, which leverages proprietary target discovery platforms to identify novel cell-surface proteins for therapeutic intervention in solid tumors.